Prasugrel, a Platelet P2Y12 Receptor Antagonist, Improves Abnormal Gait in a Novel Murine Model of Thrombotic Hindlimb Ischemia
BackgroundThe efficacy of P2Y12 inhibition for the prevention of cardiovascular events in patients with peripheral arterial disease (PAD) has been established. However, the therapeutic effects on ischemic limb complications are less clear. Accordingly, we aimed to develop a novel murine model of thr...
Main Authors: | Kousaku Ohno, Atsuyuki Tomizawa, Makoto Mizuno, Joseph A. Jakubowski, Atsuhiro Sugidachi |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2016-04-01
|
Series: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
Subjects: | |
Online Access: | https://www.ahajournals.org/doi/10.1161/JAHA.115.002889 |
Similar Items
-
Prasugrel
by: Gianluca Airoldi, et al.
Published: (2013-04-01) -
Diurnal Variability of Platelet Aggregation in Patients with Myocardial Infarction Treated with Prasugrel and Ticagrelor
by: Piotr Adamski, et al.
Published: (2022-02-01) -
No Differences in Gastrointestinal Bleeding Risk among Clopidogrel-, Ticagrelor-, or Prasugrel-Based Dual Antiplatelet Therapy
by: Viviana Laredo, et al.
Published: (2020-05-01) -
Impact of immature platelet fraction on platelet reactivity during prasugrel maintenance treatment
by: Monica Verdoia, et al.
Published: (2019-10-01) -
Biocatalytic Syntheses of Antiplatelet Metabolites of the Thienopyridines Clopidogrel and Prasugrel Using Fungal Peroxygenases
by: Jan Kiebist, et al.
Published: (2021-09-01)